120 related articles for article (PubMed ID: 12754289)
41. Expression of MUC1, MUC2, MUC5AC and MUC5B in mucinous lesions of the breast.
Kim D; Jung WH; Koo JS
Pathobiology; 2012; 79(3):144-53. PubMed ID: 22269464
[TBL] [Abstract][Full Text] [Related]
42. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies.
Dian D; Janni W; Kuhn C; Mayr D; Karsten U; Mylonas I; Friese K; Jeschke U
Onkologie; 2009 May; 32(5):238-44. PubMed ID: 19420969
[TBL] [Abstract][Full Text] [Related]
44. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin.
Paknejad M; Rasaee MJ; Tehrani FK; Kashanian S; Mohagheghi MA; Omidfar K; Bazl MR
Hybrid Hybridomics; 2003 Jun; 22(3):153-8. PubMed ID: 12954100
[TBL] [Abstract][Full Text] [Related]
45. MUC1: a target molecule for cancer therapy.
Singh R; Bandyopadhyay D
Cancer Biol Ther; 2007 Apr; 6(4):481-6. PubMed ID: 18027437
[TBL] [Abstract][Full Text] [Related]
46. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Tieu W; Pukala TL; Staudacher AH; Bezak E
Cells; 2022 Sep; 11(19):. PubMed ID: 36230945
[TBL] [Abstract][Full Text] [Related]
47. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
48. Subcellular localization of MUC1 recognized by a monoclonal antibody MY.1E12 correlates with postsurgical prognosis in differentiated-type gastric carcinomas of stage II and III.
Shinozaki E; Adachi S; Shoda J; Kawamoto T; Suzuki H; Irimura T; Ohkohchi N
Int J Oncol; 2004 Nov; 25(5):1257-65. PubMed ID: 15492813
[TBL] [Abstract][Full Text] [Related]
49. Human corneal and conjunctival epithelia express MUC1 mucin.
Inatomi T; Spurr-Michaud S; Tisdale AS; Gipson IK
Invest Ophthalmol Vis Sci; 1995 Aug; 36(9):1818-27. PubMed ID: 7635656
[TBL] [Abstract][Full Text] [Related]
50. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Bontkes HJ; Scheper RJ; Kenemans P; Verheijen RH; von Mensdorff-Pouilly S
Cancer Lett; 2007 Nov; 257(1):47-55. PubMed ID: 17692456
[TBL] [Abstract][Full Text] [Related]
51. Expression of the Tumor-associated Mucin 1 Epitope Analyzed with the Humanized PankoMab-GEX™ Antibody in Malignant and Normal Tissues of the Head and Neck.
Wiest I; Alexiou C; Friese K; Betz P; Tübel J; Goletz S; Dian D; Jeschke U
Anticancer Res; 2016 Jun; 36(6):3179-84. PubMed ID: 27272845
[TBL] [Abstract][Full Text] [Related]
52. Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion.
Quin RJ; McGuckin MA
Int J Cancer; 2000 Aug; 87(4):499-506. PubMed ID: 10918188
[TBL] [Abstract][Full Text] [Related]
53. Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro.
Shimizu M; Imai M
Biol Pharm Bull; 2008 Dec; 31(12):2288-93. PubMed ID: 19043215
[TBL] [Abstract][Full Text] [Related]
54. Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer.
Semba R; Horimoto Y; Sakata-Matsuzawa M; Ishizuka Y; Denda-Nagai K; Fujihira H; Noji M; Onagi H; Ichida M; Miura H; Watanabe J; Saito M; Saito T; Arakawa A; Irimura T
Sci Rep; 2023 Mar; 13(1):5281. PubMed ID: 37002293
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues.
Cao Y; Karsten U; Hilgers J
Tumour Biol; 1998; 19 Suppl 1():88-99. PubMed ID: 9422093
[TBL] [Abstract][Full Text] [Related]
56. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer.
Curry JM; Thompson KJ; Rao SG; Besmer DM; Murphy AM; Grdzelishvili VZ; Ahrens WA; McKillop IH; Sindram D; Iannitti DA; Martinie JB; Mukherjee P
J Surg Oncol; 2013 Jun; 107(7):713-22. PubMed ID: 23335066
[TBL] [Abstract][Full Text] [Related]
57. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
58. Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women.
Croce MV; Isla-Larrain MT; Price MR; Segal-Eiras A
Int J Biol Markers; 2001; 16(2):112-20. PubMed ID: 11471893
[TBL] [Abstract][Full Text] [Related]
59. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
Qu CF; Li Y; Song YJ; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins AC; Apostolidis C; Allen BJ
Br J Cancer; 2004 Dec; 91(12):2086-93. PubMed ID: 15599383
[TBL] [Abstract][Full Text] [Related]
60. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595.
Hughes OD; Perkins AC; Frier M; Wastie ML; Denton G; Price MR; Denley H; Bishop MC
BJU Int; 2001 Jan; 87(1):39-46. PubMed ID: 11121991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
